Indonesia Healthcare Outlook : Value Propositions and Market Entry Guides for Investors
NEW YORK, Feb. 26, 2015 /PRNewswire/ -- Methodology and Scope
This research service focuses on the Indonesian healthcare market, providing a detailed overview of the investment scenario in particular. A brief overview of the tendering process, incentives for investors, and distributor network have also been included.
This study broadly discusses the revenue or financial forecasting of the healthcare market, but does not provide a discussion of the companies which are involved with research & development (R&D) or services in details.
Company profiles of those companies which are currently or imminently prominent and or may be of interest for investors in Indonesia have been included.
The information contained in this research service was derived from published sources including the following: Government of Indonesia Websites, healthcare company websites, World Health Organization (WHO) data, World Bank data, International Monetary Fund (IMF) and press releases, public sources, Frost & Sullivan's internal data bank, and industry key opinion leaders (KOLs). Primary and secondary research methodologies were used to gather and analyse the data presented in this study.
What Does the Indonesian Healthcare Market Offer?
To Cover All Citizens by 2019
• Demand for More Hospital Beds
• Demand for More Drugs (Generics)
• Demand for More Medical Equipment
• Demand for More Diagnostic Tests
• Demand for Qualified and Skilled Healthcare Professionals
With an increase in income per capita, and the expected subsidisation of medication and hospital insurance by the government, people are likely to move away from self-medication to seek treatment in clinics and hospitals. In anticipation, a few non-hospital participants such as PT Kalbe Farma Tbk have already started planning their entry into the new private hospitals and clinics market in 2013. They also have plans for catering to affluent Indonesians who can afford out-of-pocket (OOP) payments and seek quality treatment over subsidized treatment. The World Bank estimates Indonesia's National Health Insurance, Jaminan Kesehatan Nasional (JKN), to cost $x-$x billion per year once it is fully implemented. Will that imply subsidised healthcare insurance to another x million citizens? Will that also create the demand for healthcare services in Indonesia?
What are the Teething Issues Post Implementation of National Health Insurance (JKN)?
Selected participating hospitals in the JKN have raised concerns over increasing working capital requirements after JKN implementation due to delays in receiving reimbursement from the government. One public hospital in Kalimantan, Timur, has indicated that it had received only x% of the payment for its January claims (reported on 22, February 2014). This is indicative of the teething issues which were anticipated post the implementation of JKN from January 2014. However, the hospital market is hopeful that these issues will be soon taken care of and things will improve by 2015.
How can the Private Investor Benefit from the JKN Scheme?
There has been an increase in middle-class income and healthcare spending year-on-year (YOY). Moreover, a large number of patients are likely to opt for private hospitals and clinics as well as diagnostic centres to avoid long queues in public hospitals. Due to this, the demand for medicines, equipment, and private hospitals will increase and further drive the Indonesian healthcare market 2015 onwards.
Read the full report: http://www.reportlinker.com/p02624854-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article